<DOC>
	<DOC>NCT00252759</DOC>
	<brief_summary>The purposes of this study are: - To estimate the relative risk of ILD in advanced/recurrence NSCLC patients treated with gefitinib as compared to other chemotherapy treatment, and to assess the risk factors for ILD in advanced/recurrence NSCLC patients undergoing treatment - To provide an estimate of the incidence of ILD in a group of advanced/recurrence NSCLC patients undergoing treatment</brief_summary>
	<brief_title>Iressa Case Control Study in Japan</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<criteria>Advanced/recurrence NSCLC patients who have had one or more chemotherapy regimens. Patients who are to be treated with gefitinib or chemotherapy Cohort: All advanced/recurrence NSCLC patients participating in this postmarketing clinical study Patients judged by the investigator(s) to have ILD (provisional cases) among those registered in the cohort OR Randomly selected patients without ILD (controls) for each provisional case Casecontrol study: Patients enrolled in the casecontrol study; all consenting patients with ILD as cases and approximately 4 times as many consenting patients without ILD as controls randomly selected from the cohort</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
</DOC>